NEAM
ABBV icon

New England Asset Management’s AbbVie ABBV Stock Holding History

New England Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.15M Buy
23,691
+576
+2% +$128K 0.66% 51
2025
Q4 		$5.28M Buy
23,115
+750
+3% +$171K 0.69% 47
2025
Q3 		$5.18M Buy
22,365
+125
+0.6% +$25.5K 0.68% 47
2025
Q2 		$4.13M Buy
22,240
+95
+0.4% +$17.7K 0.64% 56
2025
Q1 		$4.64M Buy
22,145
+120
+0.5% +$23.3K 0.75% 50
2024
Q4 		$3.91M Sell
22,025
-2,660
-11% -$489K 0.67% 56
2024
Q3 		$4.87M Sell
24,685
-110
-0.4% -$20.5K 0.76% 51
2024
Q2 		$4.25M Sell
24,795
-370
-1% -$61.3K 0.71% 53
2024
Q1 		$4.58M Sell
25,165
-6,575
-21% -$1.13M 0.71% 53
2023
Q4 		$4.92M Sell
31,740
-19,100
-38% -$2.78M 0.79% 46
2023
Q3 		$7.58M Sell
50,840
-1,950
-4% -$286K 1.24% 22
2023
Q2 		$7.11M Hold
52,790
– – 1.03% 28
2023
Q1 		$8.41M Sell
52,790
-2,455
-4% -$375K 1.25% 20
2022
Q4 		$8.93M Buy
55,245
+9,550
+21% +$1.46M 0.16% 25
2022
Q3 		$6.13M Sell
45,695
-29,650
-39% -$4.25M 0.1% 40
2022
Q2 		$11.5M Buy
75,345
+550
+0.7% +$84K 0.19% 16
2022
Q1 		$12.1M Buy
74,795
+650
+0.9% +$94.4K 0.19% 17
2021
Q4 		$10M Buy
74,145
+7,400
+11% +$874K 0.15% 22
2021
Q3 		$7.2M Buy
66,745
+2,700
+4% +$309K 0.13% 26
2021
Q2 		$7.21M Buy
64,045
+2,200
+4% +$248K 0.13% 25
2021
Q1 		$6.69M Buy
61,845
+850
+1% +$90.9K 0.13% 24
2020
Q4 		$6.54M Buy
60,995
+1,550
+3% +$149K 0.13% 24
2020
Q3 		$5.21M Sell
59,445
-2,050
-3% -$193K 0.12% 33
2020
Q2 		$6.04M Sell
61,495
-5,500
-8% -$484K 0.15% 22
2020
Q1 		$5.1M Buy
66,995
+3,900
+6% +$332K 0.12% 30
2019
Q4 		$5.59M Sell
63,095
-1,150
-2% -$95.5K 0.09% 33
2019
Q3 		$4.87M Buy
64,245
+10,000
+18% +$686K 0.09% 34
2019
Q2 		$3.94M Sell
54,245
-400
-0.7% -$31.4K 0.08% 45
2019
Q1 		$4.4M Buy
54,645
+2,255
+4% +$184K 0.08% 41
2018
Q4 		$4.83M Buy
52,390
+2,000
+4% +$176K 0.1% 31
2018
Q3 		$4.76M Sell
50,390
-60
-0.1% -$5.69K 0.08% 33
2018
Q2 		$4.67M Buy
50,450
+5,250
+12% +$513K 0.08% 28
2018
Q1 		$4.28M Sell
45,200
-5,900
-12% -$648K 0.08% 26
2017
Q4 		$4.94M Sell
51,100
-1,000
-2% -$94.2K 0.1% 23
2017
Q3 		$4.63M Hold
52,100
– – 0.11% 25
2017
Q2 		$3.78M Sell
52,100
-1,000
-2% -$67.2K 0.12% 27
2017
Q1 		$3.46M Buy
53,100
+5,000
+10% +$314K 0.06% 36
2016
Q4 		$3.01M Buy
48,100
+1,200
+3% +$73.2K 0.08% 34
2016
Q3 		$2.96M Buy
46,900
+2,600
+6% +$168K 0.11% 37
2016
Q2 		$2.74M Buy
44,300
+300
+0.7% +$18.3K 0.1% 43
2016
Q1 		$2.51M Sell
44,000
-10,700
-20% -$596K 0.08% 44
2015
Q4 		$3.24M Buy
54,700
+14,700
+37% +$847K 0.08% 31
2015
Q3 		$2.18M Buy
40,000
+5,100
+15% +$332K 0.06% 78
2015
Q2 		$2.35M Buy
34,900
+900
+3% +$58.8K 0.06% 73
2015
Q1 		$1.99M Buy
34,000
+200
+0.6% +$12.1K 0.05% 81
2014
Q4 		$2.21M Hold
33,800
– – 0.05% 70
2014
Q3 		$1.95M Sell
33,800
-6,400
-16% -$355K 0.05% 86
2014
Q2 		$2.27M Sell
40,200
-1,400
-3% -$73.4K 0.05% 89
2014
Q1 		$2.14M Sell
41,600
-8,400
-17% -$425K 0.05% 88
2013
Q4 		$2.64M Buy
50,000
+1,600
+3% +$78.6K 0.07% 80
2013
Q3 		$2.17M Buy
48,400
+17,900
+59% +$793K 0.06% 80
2013
Q2 		$1.26M Buy
+30,500
New +$1.33M 0.04% 91

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

New England Asset Management's ABBV Position: Q1 2026 in Review

New England Asset Management increased its AbbVie (ABBV) stake by 2.5% in Q1 2026, buying an estimated $128K and bringing the position to 23,691 shares worth $5.15M. The position accounts for 0.66% of the portfolio, ranked #51.

New England Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.1M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • New England Asset Management held 23,691 shares of AbbVie worth $5.15M as of Q1 2026.
  • New England Asset Management bought 576 AbbVie shares in Q1 2026, an estimated $128K.
  • AbbVie made up 0.66% of New England Asset Management's portfolio in Q1 2026, its #51 holding.
  • New England Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • New England Asset Management's AbbVie position peaked at $12.1M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on New England Asset Management's 13F filing for Q1 2026, filed 15 May 2026.